Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

NCT02825147 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT02825147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02825147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
July 31, 2017
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasal type extranodal nk/t-cell lymphoma